Valuation : China Biotech Services Holdings Limited

Market Cap 600M 76.53M 65.92M 62.2M 56.66M 106M 7.3B 107M 740M 285M 3.72B 287M 281M 11.82B P/E 2024
-2.49x
P/E 2025 -11.2x
Enterprise Value 983M 125M 108M 102M 92.81M 173M 11.96B 175M 1.21B 467M 6.1B 471M 460M 19.35B EV / Sales 2024
9.45x
EV / Sales 2025 15.7x
Free-Float
35.46%
Yield 2024 *
-
Yield 2025 -
08-28 China Biotech Services Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2026 CI
08-12 China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2026 CI
08-12 China Biotech Services Holdings Limited and Stella Pharma Corporation Enter Master Collaboration Agreement for Commercialisation of BNCT Drug CI
08-03 China Biotech Services Holdings Limited's Japan, Pengbo Medical Technology Co., Ltd. Present of Initial Follow-Up Findings of Boron Neutron Capture Therapy At the 22Nd Congress on Neutron Capture Therapy CI
05-18 China Biotech Services' unit disposes entire stake in PHC Medical Diagnostic Centre, others RE
04-30 China Biotech Services says He Xun resigns as executive director RE
04-30 China Biotech Services Holdings Limited Announces Resignation He Xun as Executive Director, Effective May 1, 2026 CI
04-29 China Biotech Services Holdings Limited Auditor Raises 'Going Concern' Doubt CI
03-27 China Biotech Services Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-07 China Biotech Services expects FY net loss of not more than HK$100 million RE
03-06 China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2025 CI
02-20 China Biotech Services Holdings Limited announced that it has received HKD 272.3 million in funding from Wealth Strategy Holding Ltd CI
12-30 China Biotech Services to issue convertible bonds RE
1 day+0.82%
1 week+0.82%
Current month+7.89%
1 month-7.52%
3 months+25.51%
6 months-15.75%
Current year-22.15%
1 week 0.6
Extreme 0.6
0.66
1 month 0.5
Extreme 0.5
0.67
Current year 0.3
Extreme 0.3
0.92
1 year 0.3
Extreme 0.3
1.18
3 years 0.25
Extreme 0.25
1.33
5 years 0.25
Extreme 0.25
2.64
10 years 0.16
Extreme 0.159
2.64
Manager TitleAgeSince
Director of Finance/CFO - -
Compliance Officer 55 26/05/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 60 07/08/2017
Director/Board Member 44 15/09/2017
Chairman 55 28/08/2017
Date Insider Type Main position Quantity % Market Cap. Importance
30/3/26 Other

Chairman

3,600,000 0.3690%
2/9/24 Other

Director

3,220,000 0.3300%
13/6/24 Other

Director

5,000,000 0.5191%
Change 5-day change 1-year change 3-year change Capi.($)
+0.82%+0.82%-42.52%+2.50% 75.9M
-0.09%-2.00%+32.81%+44.73% 122B
-0.15%+4.76%+1.89%+53.96% 91.33B
+0.83%0.00%-5.39%+58.47% 29.02B
-1.83%-4.01%+26.53%+81.97% 25.99B
-0.13%+0.82%-3.36%-4.47% 21.72B
-2.09%+1.91%+34.15%+252.55% 21.67B
+3.06%+1.79%-2.66%+29.54% 15.77B
-0.13%-2.21%-10.18%-3.78% 11.87B
-0.92%+1.08%+32.64%+89.77% 11.67B
Average -0.06%+0.79%+6.39%+60.53% 35.11B
Weighted average by Cap. -0.17%+0.95%+15.92%+59.97%

Financials

2024 2025
Net sales 70.51M 8.99M 7.75M 7.31M 6.66M 12.43M 858M 12.57M 86.95M 33.49M 437M 33.77M 33.03M 1.39B 73.5M 9.37M 8.08M 7.62M 6.94M 12.96M 895M 13.1M 90.64M 34.92M 456M 35.2M 34.43M 1.45B
Net income -198M -25.27M -21.77M -20.54M -18.71M -34.94M -2.41B -35.33M -244M -94.12M -1.23B -94.89M -92.81M -3.9B -68.78M -8.77M -7.56M -7.13M -6.49M -12.13M -837M -12.26M -84.82M -32.67M -427M -32.94M -32.22M -1.35B
Net Debt 169M 21.54M 18.56M 17.51M 15.95M 29.78M 2.06B 30.12M 208M 80.24M 1.05B 80.89M 79.12M 3.33B 383M 48.82M 42.06M 39.68M 36.15M 67.5M 4.66B 68.25M 472M 182M 2.37B 183M 179M 7.54B
Logo China Biotech Services Holdings Limited
China Biotech Services Holdings Ltd, formerly Rui Kang Pharmaceutical Group Investments Ltd, is an investment holding company principally engaged in the provision of medical health check services. The Company operates its business through six segments. The Medical and Health Related Services segment provides medical laboratory testing services and health check services. The Insurance Brokerage segment is engaged in the provision of brokerage services. The Immunotherapy segment provides tumor immune call therapy, immune cell storage and health management services. The Pharmaceutical Products segment is engaged in the manufacture, research and development, sale and distribution of health related and pharmaceutical products. The Securities segment is engaged in the trading of securities. The Others segment is engaged in the money lending business and provision of logistic services.
Employees
166
Date Price Change Volume
10/09/26 HK$0.6150 +0.82% 65,000
09/09/26 HK$0.6100 -3.94% 145,000
08/09/26 HK$0.6350 +0.79% 55,000
07/09/26 HK$0.6300 0.00% 40,000
04/09/26 HK$0.6300 +3.28% 70,000
  1. Stock Market
  2. Stocks
  3. 8037 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!